Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $9.53 USD
Change Today +0.18 / 1.93%
Volume 2.3M
ZIOP On Other Exchanges
Symbol
Exchange
NASDAQ CM
As of 8:10 PM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

ziopharm oncology inc (ZIOP) Snapshot

Open
$9.43
Previous Close
$9.35
Day High
$9.88
Day Low
$9.32
52 Week High
03/20/15 - $14.40
52 Week Low
10/8/14 - $2.31
Market Cap
1.2B
Average Volume 10 Days
3.5M
EPS TTM
$-0.31
Shares Outstanding
128.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ZIOPHARM ONCOLOGY INC (ZIOP)

ziopharm oncology inc (ZIOP) Related Bloomberg News

View More Bloomberg News

ziopharm oncology inc (ZIOP) Related Businessweek News

No Related Businessweek News Found

ziopharm oncology inc (ZIOP) Details

ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in collaboration with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability. The company is also developing programs in various stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System(r) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. Its pipeline includes various gene and cell-based therapeutics in both clinical and pre clinical testing which are focused on hematologic and solid tumor malignancies. ZIOPHARM Oncology, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts.

27 Employees
Last Reported Date: 02/26/15
Founded in 2003

ziopharm oncology inc (ZIOP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $700.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $238.7K
Chief Legal Officer, Executive Vice President...
Total Annual Compensation: $472.5K
Compensation as of Fiscal Year 2014.

ziopharm oncology inc (ZIOP) Key Developments

ZIOPHARM Oncology, Inc. Announces Initiation of Phase 1 Study of Ad-RTS-IL-12 Gene Therapy in Patients with Brain Cancer

ZIOPHARM Oncology, Inc. announced the initiation of a Phase 1 study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or progressive glioblastoma or Grade III malignant glioma, a form of brain cancer. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, a critical protein for stimulating an anti-cancer T cell immune response. The Phase 1 study is designed to examine a gene therapy treatment strategy for high grade gliomas with the goal of generating an anti tumor T cell immune response. Eligible patients will be stratified to one of two groups, according to clinical indication for tumor resection. One group will undergo resection plus injection and the other group will undergo stereotactic injection. Ad-RTS-hIL-12 will be injected locally in the tumor lesion, with IL-12 expression levels tightly regulated by escalating doses of the oral activator ligand veledimex. This strategy makes it feasible to control the gene therapy in vivo and to lower or terminate IL-12 expression in the event of severe or unexpected toxicities. The primary objective of the study is to determine the safety and tolerability of a single intra tumoral Ad-RTS-hIL-12 injection plus escalating oral veledimex doses. Secondary Objectives are to determine the veledimex maximum tolerated dose, the immune responses elicited by Ad-RTS-hIL-12 and veledimex, and investigator assessment of response, including the tumor objective response rate and progression-free survival, and determine overall survival, among other measures. The study is expected to enroll up to 72 subjects at up to 12 leading treatment centers. Among the centers expected to begin enrollment are the Stanford School of Medicine, Dana Farber/Brigham and Women's, the University of Chicago Pritzker School of Medicine, Cedars-Sinai/the David Geffen School of Medicine at the University of California, Los Angeles, and Northwestern Memorial Hospital.

ZIOPHARM Oncology, Inc. Announces Initiation of Phase 1b/2 Study of Ad-RTS-hIL-12 + veledimex

ZIOPHARM Oncology, Inc. announced the initiation of a Phase 1b/2 study of Ad-RTS-hIL-12 + veledimex following standard chemotherapy for the treatment of patients with locally advanced or metastatic breast cancer. The study will be conducted at the Memorial Sloan Kettering Cancer Center in New York led by principal investigator Heather L. McArthur, M.D., M.P.H., Assistant Attending Physician, Breast Medicine Service, Memorial Sloan Kettering Cancer Center. Ad-RTS-hIL-12 is a novel gene therapy candidate for the controlled expression of IL-12, an important protein for collapsing tumor stroma and stimulating an anti-cancer T cell immune response. The study is designed to examine the safety, tolerability and efficacy of Ad-RTS-hIL-12 immunotherapy in women with locally advanced or metastatic breast cancer of all subtypes. Up to 40 subjects may be enrolled in the study, including up to 20% (8 subjects) with HER2+ breast cancer. Subjects who are receiving first- or second-line standard therapy and have achieved a partial response or stable disease are eligible. Following entry into the trial, patients will go on a treatment holiday from chemotherapy and enter an immunotherapy phase of treatment. A single cycle of Ad-RTS-hIL-12, along with the oral activator ligand veledimex, will be given during the immunotherapy phase, with the goal of maintaining or improving pre-study response. Continuation of HER2-targeted antibody therapy is permitted during this immunotherapy phase for women with HER2+ disease. The primary study objective is to evaluate the safety and tolerability of Ad-RTS-hIL-12 immunotherapy. Secondary objectives include overall response rate, disease control rate and impact of treatment on tumor and serum immune biomarkers.

ZIOPHARM Oncology, Inc. and Intrexon Corporation Enters into Worldwide License and Collaboration Agreement with ARES Trading S.A

On March 27, 2015, ZIOPHARM Oncology, Inc. and Intrexon Corporation entered into a worldwide License and Collaboration Agreement or the Ares Trading Agreement with ARES Trading S.A. through which the parties established a collaboration for the research and development and commercialization of Products for the prophylactic, therapeutic, palliative or diagnostic use for cancer in humans. The Ares Trading Agreement provides for the establishment of committees composed of Ares Trading and Intrexon representatives that will govern activities in, among others, the areas of project establishment, research plans and intellectual property. The Ares Trading Agreement grants Ares Trading an exclusive, worldwide, royalty-bearing, sub-licensable license under the company's and Intrexon's patents, know-how and proprietary platform of research tools and technology necessary for the company and Intrexon to perform their tasks directed towards the design, identification, culturing, and/or production of genetically modified cells to generate and test Chimeric Antigen Receptor T-Cell Products solely for the development, regulatory approval and commercialization of Products containing such Chimeric Antigen Receptor T-Cell Products pursuant to the licenses granted in clauses (b) and (c) of this paragraph; develop and commercialize Products in the Field, worldwide, provided that such Products are not Out-of-Scope Products where Ares Trading has not exercised its Option; and commercialize the chimeric antigen receptor for Products. Ares Trading will pay an upfront fee of $115.0 million to Intrexon as consideration for entry into the Ares Trading Agreement. Intrexon will pay 50% of the fee to the company in accordance with the ECP Amendment. Ares Trading will, pursuant to the terms of the Ares Trading Agreement, pay Intrexon certain fees for the research and development activities related to the products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZIOP:US $9.53 USD +0.18

ZIOP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aduro Biotech Inc $27.99 USD +0.28
Advaxis Inc $18.76 USD +1.10
Exact Sciences Corp $22.68 USD -0.69
Genocea Biosciences Inc $9.81 USD -0.17
Inovio Pharmaceuticals Inc $8.09 USD -0.18
View Industry Companies
 

Industry Analysis

ZIOP

Industry Average

Valuation ZIOP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 730.6x
Price/Book 30.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 879.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIOPHARM ONCOLOGY INC, please visit www.ziopharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.